Nido Biosciences Website Privacy Policy

Nido Biosciences, Inc. (“Nido”) recognizes the importance of protecting the privacy of information we may receive from visitors to our website (this “Website”). You may visit our Website without telling us anything about yourself, and our Website only collects the technical information disclosed in this Privacy Policy. If you contact us (through the Contact Us page on this Website) and choose to provide personally identifiable information or other personal data, we will utilize it to respond to your inquiry. We do not collect or maintain personally identifiable information for resale purposes or share your information with any other company or organization.

Notification of Changes to This Policy

Nido is continually improving and adding new functionality and features to our Website and improving and adding to our existing product line, services, and programs. Because of these ongoing changes, changes in the law and the changing nature of technology, Nido’s data practices will change from time to time. If our data practices change, Nido will post the changes on this page to notify you of such changes. Changes to the Privacy Policy will become effective when posted. Unless stated otherwise, our current Privacy Notice applies to all personal data that we have about you (if any). We stand behind the promises we make, however, and will not materially change our policies and practices to make them less protective of personal data collected in the past without the consent of affected individuals. We encourage you to check this page frequently by clicking on the Privacy Policy link on any page of our Website.

Personal Data Collected Through the Website

The only personal data Nido currently collects through this Website is the information you send to us when you contact Nido with your direct questions and comments through the Contact Us page on this Website.

Security

Nido takes certain precautions to protect our users’ information and to limit the risk that it will be accessed without authorization, including use of certain industry standard technologies and practices. We cannot, however, ensure or warrant the security of any information you transmit to Nido, and you do so at your own risk. If Nido learns of a security systems breach, we may attempt to notify you electronically so that you can take appropriate protective steps. Nido may post a notice on the Website if a security breach occurs. Depending on where you live, you may have a legal right to receive notice of a security breach in writing. To receive a free written notice of a security breach, or if you have any questions about the security of the Website, please email us at contact@nido.com.

Unsecured Email Warning

Please note that any information you send to Nido via email is sent via an unsecured email link. Due to the nature of the Internet, there is a possibility that unsecured (unencrypted) email could be intercepted and read by third parties. Nido assumes no responsibility for interception of confidential information (including in a resume or CV) that you send in an unsecured (unencrypted) email message.

Use of Personal Data Collected Through This Website

Nido does not sell, trade, or rent your personal data to others. Nido uses the information you provide to respond to your email, answer your question or resolve your problem. Nido and our affiliates also use this information to help us improve the content and functionality of our Website, to better understand our customers and markets, and to improve our products and services. Nido and our affiliates may use this information to contact you in the future to tell you about products or services we believe will be of interest to you. If we do so, each communication we send you will contain instructions permitting you to “opt-out” of receiving future communications.

Anonymous Data Collected Through This Website

In addition to the information you provide when you use our Website, Nido uses technology to collect anonymous information about the use of our Website. For example, we use technology to track how many visitors access our Website, the date and time of their visit, the length of their stay, and which pages they view. We also use technology to determine which Web browsers our visitors use and the address from which they accessed our site (for example, if they connected to this Website by clicking on our link from another website). This technology does not identify you personally. It simply enables us to compile statistics about our visitors and their use of our Website. Nido and our affiliates use this anonymous data and share it with third parties to improve the content and functionality of our Website, to better understand our customers and markets, and to improve our products and services.

Cookies

To collect the anonymous data described in the preceding paragraph, Nido may use temporary “cookies” that collect the first level domain name of the user (for example, if your email address is “fred@123.com,” the cookie collects the “123.com” portion of your email address) and the date and time you accessed this Website. Cookies by themselves cannot be used to discover the identity of the user. A cookie is a small piece of information which is sent to your browser and stored on your computer’s hard drive. Cookies keep track of non-personal information such as the URL that you came from and go to next, your navigation through the Website (for example, the advertisements that you click on), the browser and operating system that you use, and your IP address. Cookies do not damage your computer. You can set your browser to notify you when you receive a cookie. This enables you to decide if you want to accept it or not. The Help portion of the toolbar on most browsers will tell you how to prevent your browser from accepting new cookies, how to have the browser notify you when you receive a new cookie, or how to disable cookies altogether. Additionally, you can disable or delete similar data used by browser add-ons, such as Flash cookies, by changing the add-on’s settings or visiting the website of its manufacturer. At the present time, Nido only uses temporary or “session” cookies. These cookies expire when your browser window is closed.

Disclosure of Your Personal Data

Nido may share some or all of the personal data collected through this Website with our affiliates, who will only use this data in accordance with this Privacy Policy. Nido and our affiliates may share personal data collected through this Website with third-party vendors who act for or on behalf of Nido or our affiliates, for example, companies that provide support services to us, including data processing services, or that help us market our products and services. These companies may need information about you in order to perform their functions. These companies are not authorized to use the information we share with them for any other purpose. In addition, there may be some other, limited circumstances in which Nido or our affiliates may share or transfer the personal data in our databases, for example, to comply with a legal requirement, to enforce the Terms and Conditions governing the use of this Website, to protect your interests, or in the event of a corporate sale, merger, reorganization, dissolution or similar event.

Link to Other Sites

This Privacy Policy forms part of our Website Terms and Conditions and as such shall be governed by and construed in accordance with the laws of the Massachusetts as further provided in the Terms and Conditions.

Governing Law

This Privacy Policy applies only to Nido. Nido and our affiliates operate many different types of websites for different purposes and in different countries where different laws may apply. If you visit one of our affiliates’ Website, please take a moment to review the privacy policy posted on that site to learn what personal data may be collected through that site and how it is processed. This Website contains hyperlinks to websites that are not operated by Nido or one of our affiliates. These hyperlinks are provided for your reference and convenience only and do not imply any endorsement of the activities of these third-party websites or any association with their operators. Nido does not control these websites and is not responsible for their data practices. We urge you to review the privacy policy posted on any website you visit before using the site or providing any personal data about yourself.

Questions About Our Privacy Policy

If you have any questions about this Privacy Policy or concerns about the way Nido processes your personal data, please contact us directly through the website.

Scroll to Top

Deborah Palestrant, Ph.D., M.B.A.

Director

Deborah Palestrant, Ph.D., M.B.A joined 5AM Ventures in 2018 as Partner and Executive Chair of 4:59 Initiative. Previously, Dr. Palestrant was Vice President of Corporate Development & Strategy at Relay Therapeutics, where she executed business strategy including alliances, partnerships, and other collaborations and led communications. She has over 15 years of life sciences industry experience including drug discovery, company creation, operations, business development, and strategy. Following her postdoctoral fellowship, Dr. Palestrant was a lab head at the Novartis Institutes for Biomedical Research, where she advanced multiple structure-based drug discovery programs. In 2010, Dr. Palestrant joined Third Rock Ventures as a senior associate and helped to build and launch Blueprint Medicines (NASDAQ: BPMC). Upon its launch, Dr. Palestrant served an interim role in operations at Blueprint Medicines. Subsequent to her return to Third Rock Ventures, Dr. Palestrant helped to conceive and launch Editas Medicine (NASDAQ: EDIT), and as part of the original founding team, she led the business development group until joining Relay Therapeutics. Dr. Palestrant holds a Ph.D. in biochemistry and molecular biophysics from Columbia University, an M.B.A from Northeastern University, and was Damon Runyon Cancer Research Foundation Postdoctoral Fellow at The Scripps Research Institute. She is based in the Boston, MA office.

Kouki Harasaki, Ph.D., M.B.A.

Director

Kouki Harasaki is the Founding / Managing Partner at Bioluminescence Ventures.

Dr. Harasaki has over 25 years of biomedical science experience working across major health systems, research institutes, biopharmaceutical corporations, technology companies, and venture capital firms. He has led over $600M in financing deals that have funded over 25 therapeutics programs across stages (discovery to marketed), across therapeutic areas (CVM, Immunology, Oncology, Neuro/CNS), and across modalities (small molecule, biologics, genome editing, cell therapy).

Prior to founding Bioluminescence Ventures, he was a Managing Director at M12 / Microsoft Ventures, where he led Life Science investments and helped develop Microsoft Life Science corporate strategy. Prior to M12, Dr. Harasaki was a senior Partner at Andreessen Horowitz, where he managed four Bio Fund Partners and worked across the portfolio of 25+ Bio Fund companies.

Prior to his time in venture, Dr. Harasaki held Drug Discovery, Animal Pharmacology, Strategy, Finance, and Business Development roles at Novartis AG and Baxalta/Shire. He holds a B.A. in Molecular/Cell Biology and Asian Studies from Cornell University, an M.B.A. from Harvard Business School, where he was a Robert S. Kaplan Fellow, and received his Ph.D. in Clinical Biochemistry from the University of Cambridge, where he was a Wellcome Trust Fellow.

Andrew Hedin, M.B.A.

Director

Andrew is a venture capitalist focused on high-growth biotechnology and healthcare companies. He is a partner at Bessemer Venture Partners where he has served on the board or been involved with investments including Kymera Therapeutics (NASDAQ:KYMR), TScan Therapeutics (NASDAQ:TCRX), Nido Biosciences, Peptone, Rimsys, Collective Medical, Bright Health (NYSE:BHG) and multiple stealth startups. Prior to joining Bessemer in 2015, Andrew worked at F-Prime Capital, Fidelity’s healthcare-focused venture capital fund where he invested in early-stage biotech and digital health companies, as well as Leerink Partners as an advisor to the biopharma industry. He received his M.B.A. with honors from The Wharton School at the University of Pennsylvania and his B.A. in Biological Basis of Behavior (Neuroscience) and Healthcare Management from the University of Pennsylvania.

Jackie Grant, M.B.A., Ph.D.

Director

Jackie has over 15 years of life sciences experience, including science, research, business development and venture investing. She is a principal at Abingworth. Prior, she worked for SV Life Sciences and Genentech. She received her Ph.D. in Neuroscience and Neuroimmunology from Stanford School of Medicine and her M.B.A. from Stanford School of Business, and she holds a B.S. in Biology from Boston College.

Jamil M. Beg, Master of Biotechnology, M.B.A.

Director

Jamil is a life science investor and operator focused on advancing breakthrough science into transformational medicines for patients. He joined 5AM Ventures in 2017 and is a Partner based in the Boston office. Mr. Beg serves on the boards of Nido Biosciences, Kinaset Therapeutics, and several stealth startups through 5AM’s 4:59 Initiative. Since joining 5AM, he has been involved with investments in Akouos (NASDAQ: AKUS, acquired by Eli Lilly), Aprea (NASDAQ: APRE), and RallyBio (NASDAQ: RLYB). He partners with founders and entrepreneurs to establish and build biotech startups and often steps into senior executive operating roles, including serving as Founding CEO of Nido Biosciences.  Over his career, Mr. Beg has been involved in over twenty private financings, seven public offerings, and three M&A transactions. He’s operated in six venture-backed startups and contributed to the advancement of five FDA approved products.

Prior to 5AM, Mr. Beg operated at Sage Therapeutics (NASDAQ: SAGE) where he advanced the company through business development, corporate strategy, and commercialization roles. Previously, Mr. Beg was an investment professional at Quaker Partners and involved with investments in Transave Inhalation Therapeutics (acquired by Insmed), NuPathe (NASDAQ: PATH, acquired by Teva), EKR Therapeutics (acquired by Cornerstone Therapeutics), and Cempra (NASDAQ: CEMP). Mr. Beg started his career at Cambridge Pharma Consultancy, a management consulting firm for the biopharma industry.

Mr. Beg earned his B.S.E. in Bioengineering and Master of Biotechnology degrees from the University of Pennsylvania. He earned his M.B.A. in Healthcare Management and Entrepreneurial Management from The Wharton School of the University of Pennsylvania where he was a recipient of the Henry J. Kaiser Family Foundation Merit Award.

Mike Clayman, M.D.

Chairman

Mike Clayman, M.D., co-founded Flexion Therapeutics in 2007 and served as president, CEO and a director from inception until its acquisition by Pacira Biosciences in November, 2021. During his tenure Dr. Clayman guided the discovery and development of ZILRETTA® for osteoarthritis-related knee pain. He also serves as chairman of the boards of Anokion SA, a Swiss biotechnology company focused on treating autoimmune disease, and Ribometrix, a US biotechnology company that discovers and develops novel small molecule medicines targeting RNA.

Before founding Flexion, Dr. Clayman had a distinguished career at Eli Lilly and Company, leading numerous divisions engaged in a broad range of activities, from discovery research to clinical investigation to global regulatory affairs. Among his roles, he served as general manager of Chorus, Lilly’s early-phase development accelerator, and as vice president of Lilly Research Laboratories. Prior to Lilly, Dr. Clayman was an assistant professor in the School of Medicine at the University of Pennsylvania, where his research centered on the immunopathogenesis of renal disease.

Dr. Clayman is the recipient of the Physician Scientist Award from the National Institutes of Health. He holds a B.A. from Yale University and an M.D. from the University of California, San Diego School of Medicine.

mark-headshot-temporary

Marc Swikalus, M.B.A., C.P.A.

Vice President of Finance

Marc has been Vice President of Finance at Nido Biosciences since March 2024, having previously served as the company’s Controller since November 2021. He has 25 years of experience working in the biopharmaceutical development, software and public accounting industries. Prior to joining Nido Bio, he held positions at Acorda Therapeutics, Ziopharm Oncology, PegaSystems and Viacell.

Marc holds a bachelor’s degree in accounting from Bentley University and an MBA from Western New England University. He is a Certified Public Accountant.

photo_christina-willwerth-v2

Christina Willwerth

Chief Operating Officer

Christina has been Chief Operating Officer at Nido Biosciences since April 2023 and has 30 years of experience in biopharmaceutical development and business operations. Prior to joining Nido Bio, she was Chief Strategy Officer at Flexion Therapeutics, leading corporate strategy and business prioritization, program/portfolio management and human resources. Christina spent over 12 years in executive leadership roles building Flexion from its early financing, through pipeline evolution, development and commercialization of Zilretta®, and acquisition of the company, with influence across all business areas.  Prior to joining Flexion, she was Vice President, Product Development and a member of the Executive Management team at Viacell, Inc. with cross-functional responsibility for the company’s cellular therapy and fertility preservation development programs. Christina also previously served as Senior Director, Product Development at The Medicines Company (TMC), focused on cardiovascular therapy clinical and product development (Angiomax®), and held ascendant clinical/product development roles at TMC, Astra Pharmaceuticals and Biopure Corporation.

Christina holds a bachelor’s degree in biology with high distinction from Worcester Polytechnic Institute.